CG Oncology Inc

CG Oncology CEO’s bulk buy at $1.72 signals a bullish insider cue, hinting at upcoming trial results that could propel the stock beyond its 52‑week high.

CEO Kuan Arthur’s recent CG Oncology stock purchase signals insider confidence—learn what this means for investors and future valuation prospects.

Mulay James’s strategic buy‑low, sell‑high trades in CG Oncology stock reveal insider confidence and long‑term upside, balancing liquidity with future value.